| Literature DB >> 35182757 |
Kristjan E Hjorleifsson1, Solvi Rognvaldsson2, Hakon Jonsson2, Arna B Agustsdottir2, Margret Andresdottir2, Kolbrun Birgisdottir2, Ogmundur Eiriksson2, Elias S Eythorsson3, Run Fridriksdottir2, Gudmundur Georgsson2, Kjartan R Gudmundsson2, Arnaldur Gylfason2, Gudbjorg Haraldsdottir2, Brynjar O Jensson2, Adalbjorg Jonasdotti2, Aslaug Jonasdottir2, Kamilla S Josefsdottir4, Nina Kristinsdottir2, Borghildur Kristjansdottir2, Thordur Kristjansson2, Droplaug N Magnusdottir2, Runolfur Palsson5, Louise le Roux2, Gudrun M Sigurbergsdottir2, Asgeir Sigurdsson2, Martin I Sigurdsson6, Gardar Sveinbjornsson2, Emil Aron Thorarensen2, Bjarni Thorbjornsson2, Marianna Thordardottir4, Agnar Helgason7, Hilma Holm2, Ingileif Jonsdottir8, Frosti Jonsson2, Olafur T Magnusson2, Gisli Masson2, Gudmundur L Norddahl2, Jona Saemundsdottir2, Patrick Sulem2, Unnur Thorsteinsdottir8, Daniel F Gudbjartsson9, Pall Melsted10, Kari Stefansson8.
Abstract
OBJECTIVES: The spread of SARS-CoV-2 is dependent on several factors, both biological and behavioural. The effectiveness of nonpharmaceutical interventions can be attributed largely to changes in human behaviour, but quantifying this effect remains challenging. Reconstructing the transmission tree of the third wave of SARS-CoV-2 infections in Iceland using contact tracing and viral sequence data from 2522 cases enables us to directly compare the infectiousness of distinct groups of persons.Entities:
Keywords: COVID-19; Outbreak reconstruction; SARS-CoV-2; Transmission tree; Vaccination strategy
Mesh:
Year: 2022 PMID: 35182757 PMCID: PMC8849849 DOI: 10.1016/j.cmi.2022.02.012
Source DB: PubMed Journal: Clin Microbiol Infect ISSN: 1198-743X Impact factor: 13.310
Fig. 1(A) Daily cases during the third wave of SARS-CoV-2 infections in Iceland, excluding cases diagnosed at the border. On October 15, 2020, went below 1 outside of quarantine for the first time and stayed below 1 except for the time period covering the hospital outbreak. Based on this observation, we split the outbreak into a growth phase before October 15 (red dashed line) and a decline phase from then until the end of January 2021. (B) (i) When determining who infected a person, initially all diagnosed cases are equally likely. (ii) Quarantine, diagnosis, and dates of symptom onset make some people more likely than others, assuming specific incubation time and generation time distributions. (iii) Contact tracing data make certain transmissions very likely but do not enable us to disregard others. (iv) Given the viral haplotypes, we can disregard transmissions where the haplotypes are incompatible (i.e. neither is derived from the other) and in some cases determine the direction of the transmission, in cases where de novo mutations occur between generations. (C) We use real-world data and the tree structure to infer the latent data for each diagnosed case. The < symbol indicates that the date on the left needs to precede the date on the right. For each diagnosed person, we infer the ancestor (i.e. the person who infected them), the date of infection, and the number of transmissions separating the ancestor and the person, . (D) One instance of a reconstructed transmission tree for the third wave in Iceland.
Number of people in different groups diagnosed in the growth phase (until October 15, 2020) and decline phase (after October 15, 2020) of the third wave of SARS-CoV-2 infections in Iceland and their estimated effective reproduction number
| Group | Overall | Growth phase | Decline phase | |||
|---|---|---|---|---|---|---|
| n (%) | n (%) | n (%) | ||||
| Whole sample | 2522 (100) | 1.00 | 1442 (100) | 1.17 (1.09–1.27) | 1080 (100) | 0.77 (0.70–0.85) |
| Outside of quarantine | 1247 (49) | 1.31 (1.21–1.43) | 776 (54) | 1.45 (1.32–1.62) | 471 (44) | 1.08 (0.93v1.25) |
| In quarantine | 1275 (51) | 0.69 (0.66–0.73) | 666 (46) | 0.84 (0.78–0.91) | 609 (56) | 0.53 (0.49v0.57) |
| Short quarantine | 564 (22) | 0.89 (0.83–0.96) | 340 (24) | 1.02 (0.93–1.13) | 224 (21) | 0.70 (0.62–0.78) |
| Long quarantine | 711 (28) | 0.54 (0.50–0.58) | 326 (23) | 0.66 (0.58–0.74) | 385 (36) | 0.43 (0.39–0.48) |
| Adults (age ≥16 y) | 2164 (86) | 1.06 (0.98–1.12) | 1269 (88) | 1.22 (1.13–1.32) | 895 (83) | 0.82 (0.74–0.91) |
| Children (age 0–15 y) | 358 (14) | 0.66 (0.59–0.73) | 173 (12) | 0.80 (0.69–0.93) | 185 (17) | 0.53 (0.45–0.62) |
| Working age (16–66 y) | 1921 (76) | 1.08 (1.01–1.16) | 1171 (81) | 1.25 (1.15–1.37) | 750 (69) | 0.82 (0.73–0.92) |
| Outside of working age | 601 (24) | 0.74 (0.66–0.84) | 271 (19) | 0.83 (0.74–0.92) | 330 (31) | 0.66 (0.54–0.81) |
Fig. 2(A) for those diagnosed while in quarantine and those diagnosed outside of quarantine, respectively. The shaded area represents the 95% CI for the mean, and the dashed lines show the dates of social restrictions imposed. (B) Effective reproduction number of those diagnosed outside of quarantine compared with those diagnosed in quarantine. Error bars reflect the 95% CI of the mean. (C) Effective reproduction number of those diagnosed outside of quarantine, those diagnosed after 1 to 2 days in quarantine, and those diagnosed after ≥3 days in quarantine. (D) Effective reproduction number stratified by age.
Fig. 3Simulations of the estimated final size of the third wave at a given population prevalence of vaccination. Solid lines show the mean size of the outbreak, and shaded areas represent 2.5% to 97.5% quantiles. As a benchmark, we compared the vaccination strategies by the lowest proportion of adults who would have needed to be vaccinated such that the final size of the third wave would have been 100 persons (4% of the observed outbreak) on average. (A) Using the actual vaccination scheme for at-risk groups and front-line workers, up to 29% of the adult population, and using three separate vaccination strategies from 29% to 100%: age-descending, age-ascending, and uniformly at random. Modelled vaccinations beyond the 29% mark are assumed to have an efficacy of 60%. (B) Simulations of the size of the third wave, assuming 60% vaccine efficacy, under the three different vaccination strategies, starting with no vaccinations and concluding with 100% of the adult population vaccinated. (C) Same simulation as in (A), but all vaccinations are assumed to have an efficacy of 90% (both first and second dose administered). (D) Same simulation as in (B), but assuming 90% vaccine efficacy.
Lowest proportion of adults who would have needed to be vaccinated such that the final size of the third wave would have been 100 persons on average
| Model | Proportion of adults vaccinated (%), mean (range) | ||
|---|---|---|---|
| Age, descending | Age, ascending | Uniform at random | |
| Actual vaccinations/first dose | 79.2 (67.6–89.4) | 64.1 (53.7–75.7) | 72.3 (56.1–85.1) |
| Actual vaccinations/second dose | 66.2 (57.1–72.1) | 52.8 (42.4–58.4) | 54.5 (43.7–63.1) |
| First dose | 81.1 (71.8–89.6) | 50.4 (38.5–69.2) | 70.0 (50.0–86.5) |
| Second dose | 66.8 (59.9–72.4) | 35.0 (29.4–40.1) | 47.0 (33.6–57.5) |
The former two models use actual vaccination numbers up to the 29% mark and extrapolate from there using the three strategies. The latter two models start from zero.